[96a5a0]: / output / allTrials / identified / NCT03271073_identified.json

Download this file

650 lines (650 with data), 27.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
{
"info": {
"nct_id": "NCT03271073",
"official_title": "A Exploratory Study of Apatinib in Combination With S1 in Patients With Advanced Gastric Evaluating the Efficacy and Safety",
"inclusion_criteria": "1. Adult patients, aged between 18 and 75 years old;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;\n3. Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC) , including adenocarcinoma of the gastroesophageal junction ,one or more measurable or nonmeasurable evaluable lesions per RECIST 1.1;\n4. Failure or intolerance to at least one prior line of systemic chemotherapy regimen;\n5. Adequate liver, renal, heart, and bone-marrow functions ( hemoglobin≥ 80g/L, platelets ≥ 100 × 10*9/L, neutrophil ≥1.5 × 10*9/L, total bilirubin ≤1.5 ×ULN, and serum transaminase≤2.5×ULN);\n6. Expected survival of ≥ 12 weeks.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "1. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than ClassI; I-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class I cardiac dysfunction;\n2. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;\n3. Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;\n4. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);\n5. Previous treatment with VEGFR inhibitor (i.e. Apatinib, sorafenib, sunitinib);\n6. With psychotropic drug abuse history and can't get rid of or mental disorder patients;\n7. Associated with CNS (central nervous system) metastases;\n8. Active bacterial infections;\n9. Pregnant or breast-feeding women;\n10. Any other condition that might place the patient at undue risk or preclude a patient from completing the study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Adult patients, aged between 18 and 75 years old;",
"criterions": [
{
"exact_snippets": "Adult patients",
"criterion": "age group",
"requirements": [
{
"requirement_type": "expected value",
"expected_value": "adult"
}
]
},
{
"exact_snippets": "aged between 18 and 75 years old",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 75,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "3. Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC) , including adenocarcinoma of the gastroesophageal junction ,one or more measurable or nonmeasurable evaluable lesions per RECIST 1.1;",
"criterions": [
{
"exact_snippets": "Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC)",
"criterion": "adenocarcinoma of gastric cancer",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "histologically"
},
{
"requirement_type": "stage",
"expected_value": [
"advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "adenocarcinoma of the gastroesophageal junction",
"criterion": "adenocarcinoma of the gastroesophageal junction",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "one or more measurable or nonmeasurable evaluable lesions per RECIST 1.1",
"criterion": "evaluable lesions",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesions"
}
},
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"nonmeasurable"
]
},
{
"requirement_type": "evaluation standard",
"expected_value": "RECIST 1.1"
}
]
}
]
},
{
"line": "4. Failure or intolerance to at least one prior line of systemic chemotherapy regimen;",
"criterions": [
{
"exact_snippets": "Failure or intolerance to at least one prior line of systemic chemotherapy regimen",
"criterion": "prior systemic chemotherapy regimen",
"requirements": [
{
"requirement_type": "failure or intolerance",
"expected_value": true
},
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "line"
}
}
]
}
]
},
{
"line": "5. Adequate liver, renal, heart, and bone-marrow functions ( hemoglobin≥ 80g/L, platelets ≥ 100 × 10*9/L, neutrophil ≥1.5 × 10*9/L, total bilirubin ≤1.5 ×ULN, and serum transaminase≤2.5×ULN);",
"criterions": [
{
"exact_snippets": "Adequate liver, renal, heart, and bone-marrow functions",
"criterion": "liver, renal, heart, and bone-marrow functions",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "hemoglobin≥ 80g/L",
"criterion": "hemoglobin level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 80,
"unit": "g/L"
}
}
]
},
{
"exact_snippets": "platelets ≥ 100 × 10*9/L",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100,
"unit": "10*9/L"
}
}
]
},
{
"exact_snippets": "neutrophil ≥1.5 × 10*9/L",
"criterion": "neutrophil count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1.5,
"unit": "10*9/L"
}
}
]
},
{
"exact_snippets": "total bilirubin ≤1.5 ×ULN",
"criterion": "total bilirubin level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "ULN"
}
}
]
},
{
"exact_snippets": "serum transaminase≤2.5×ULN",
"criterion": "serum transaminase level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "ULN"
}
}
]
}
]
},
{
"line": "6. Expected survival of ≥ 12 weeks.",
"criterions": [
{
"exact_snippets": "Expected survival of ≥ 12 weeks.",
"criterion": "expected survival",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "healthy volunteers",
"requirements": [
{
"requirement_type": "participation",
"expected_value": true
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than ClassI; I-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class I cardiac dysfunction;",
"criterions": [
{
"exact_snippets": "poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg)",
"criterion": "arterial hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": "poor-controlled"
},
{
"requirement_type": "systolic blood pressure",
"expected_value": {
"operator": ">",
"value": 140,
"unit": "mmHg"
}
},
{
"requirement_type": "diastolic blood pressure",
"expected_value": {
"operator": ">",
"value": 90,
"unit": "mm Hg"
}
}
]
},
{
"exact_snippets": "Coronary heart disease greater than ClassI",
"criterion": "coronary heart disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "> Class I"
}
]
},
{
"exact_snippets": "I-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms)",
"criterion": "arrhythmia",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "I-level"
},
{
"requirement_type": "QT interval prolongation",
"expected_value": [
">= 450 ms for man",
">= 470 ms for woman"
]
}
]
},
{
"exact_snippets": "Class I cardiac dysfunction",
"criterion": "cardiac dysfunction",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "Class I"
}
]
}
]
},
{
"line": "2. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;",
"criterions": [
{
"exact_snippets": "high gastrointestinal bleeding risk",
"criterion": "gastrointestinal bleeding risk",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "high"
}
]
},
{
"exact_snippets": "local active ulcer lesions",
"criterion": "ulcer lesions",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
},
{
"requirement_type": "location",
"expected_value": "local"
}
]
},
{
"exact_snippets": "positive fecal occult blood test (++)",
"criterion": "fecal occult blood test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "history of black stool",
"criterion": "black stool",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "vomiting blood in the past 2 months",
"criterion": "vomiting blood",
"requirements": [
{
"requirement_type": "history",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "months"
}
}
]
}
]
},
{
"line": "3. Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;",
"criterions": [
{
"exact_snippets": "Abnormal Coagulation (INR>1.5",
"criterion": "INR",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "Abnormal Coagulation ... APTT>1.5 UNL",
"criterion": "APTT",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "UNL"
}
}
]
},
{
"exact_snippets": "tendency of bleed",
"criterion": "tendency of bleed",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "4. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);",
"criterions": [
{
"exact_snippets": "inability to swallow",
"criterion": "ability to swallow",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "chronic diarrhea",
"criterion": "chronic diarrhea",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "intestinal obstruction",
"criterion": "intestinal obstruction",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "5. Previous treatment with VEGFR inhibitor (i.e. Apatinib, sorafenib, sunitinib);",
"criterions": [
{
"exact_snippets": "Previous treatment with VEGFR inhibitor (i.e. Apatinib, sorafenib, sunitinib)",
"criterion": "previous treatment with VEGFR inhibitor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "6. With psychotropic drug abuse history and can't get rid of or mental disorder patients;",
"criterions": [
{
"exact_snippets": "psychotropic drug abuse history",
"criterion": "psychotropic drug abuse history",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "can't get rid of",
"criterion": "inability to cease psychotropic drug use",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "mental disorder patients",
"criterion": "mental disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "7. Associated with CNS (central nervous system) metastases;",
"criterions": [
{
"exact_snippets": "Associated with CNS (central nervous system) metastases",
"criterion": "CNS metastases",
"requirements": [
{
"requirement_type": "association",
"expected_value": true
}
]
}
]
},
{
"line": "8. Active bacterial infections;",
"criterions": [
{
"exact_snippets": "Active bacterial infections",
"criterion": "bacterial infections",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
}
]
}
]
},
{
"line": "9. Pregnant or breast-feeding women;",
"criterions": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breast-feeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "10. Any other condition that might place the patient at undue risk or preclude a patient from completing the study.",
"criterions": [
{
"exact_snippets": "Any other condition that might place the patient at undue risk",
"criterion": "condition causing undue risk",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "condition that might ... preclude a patient from completing the study",
"criterion": "condition precluding study completion",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}